Trials / Completed
CompletedNCT04573556
A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.
Multicenter, Post-marketing Observational (Non-interventional) Study to Evaluate the Safety of DAYVIGO Tablet in Patients With Insomnia.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 550 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 100 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the incidence of somnolence, parasomnia, narcoleptic symptoms, and suicidal ideation/suicidal behavior after administration of lemborexant (DAYVIGO) in daily practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lemborexant | Lemborexant oral tablets. |
Timeline
- Start date
- 2020-10-17
- Primary completion
- 2022-03-17
- Completion
- 2022-03-17
- First posted
- 2020-10-05
- Last updated
- 2022-04-05
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04573556. Inclusion in this directory is not an endorsement.